Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Matthew Balk currently holds 1,787,796 shares of AzurRx BioPharma, Inc. (AZRX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Matthew Balk has been a net seller of AZRX stock. They have purchased $0 and sold $1.0M worth of shares.
Matthew Balk's most recent insider trade was on Jun 30, 2017, when they sold 100,000 shares at $3.00 per share.
Matthew Balk serves as Executive at AzurRx BioPharma, Inc. (AZRX). They have executed 4 insider transactions totaling $1.0M over their tenure at the company.
Matthew Balk holds the position of Executive at AzurRx BioPharma, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 9 years and currently hold a stake valued at $0.
Matthew Balk has shown a selling trading pattern, with $0 in total purchases and $1.0M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Matthew Balk was on Jun 30, 2017, when they sold $300.0K worth of AZRX shares. This transaction involved 100,000 shares at $3.00 per share.
Matthew Balk currently owns 1,787,796 shares of AzurRx BioPharma, Inc. (AZRX), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Matthew Balk's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Matthew Balk has 4 Form 4 filings on record as an insider at AzurRx BioPharma, Inc..
Set alerts for Matthew Balk and 40,000+ other insiders.